Cover Image
市場調查報告書

Cumberland Pharmaceuticals, Inc.的產品平台分析

Cumberland Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321965
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
Cumberland Pharmaceuticals, Inc.的產品平台分析 Cumberland Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年09月23日 內容資訊: 英文 25 Pages
簡介

Cumberland Pharmaceuticals, Inc.是總公司設立於美國的製藥企業。從事醫院,急救治療,未滿足的醫療需求,消化器官系統疾病處方藥之收購、開發、商品化等。產品有預防過度服用普拿疼 (Acetaminophen)造成的肝臟病變、消化系統專業醫生處方之便秘藥、解熱止痛藥等。

本報告提供Cumberland Pharmaceuticals, Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Cumberland Pharmaceuticals, Inc. 的基本資料

  • Cumberland Pharmaceuticals, Inc. 概要
  • 主要資訊
  • 企業資料

Cumberland Pharmaceuticals, Inc. :R&D概要

  • 主要的治療範圍

Cumberland Pharmaceuticals, Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Cumberland Pharmaceuticals, Inc. :開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Cumberland Pharmaceuticals, Inc. :藥物簡介

  • ifetroban
  • Isocitrate
  • Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury
  • AC-301

Cumberland Pharmaceuticals, Inc. :開發平台分析

  • 標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Cumberland Pharmaceuticals, Inc. :最新的開發平台資訊

Cumberland Pharmaceuticals, Inc. :開發暫停中的計劃

Cumberland Pharmaceuticals, Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07609CDB

Summary

Global Markets Direct's, 'Cumberland Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Cumberland Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cumberland Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Cumberland Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Cumberland Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Cumberland Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Cumberland Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Cumberland Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Cumberland Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Cumberland Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cumberland Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Cumberland Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Cumberland Pharmaceuticals, Inc. Snapshot
    • Cumberland Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Cumberland Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Cumberland Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Cumberland Pharmaceuticals, Inc. - Pipeline Products Glance
    • Cumberland Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Cumberland Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Cumberland Pharmaceuticals, Inc. - Drug Profiles
    • ifetroban
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Isocitrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cumberland Pharmaceuticals, Inc. - Pipeline Analysis
    • Cumberland Pharmaceuticals, Inc. - Pipeline Products by Target
    • Cumberland Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Cumberland Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Cumberland Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Cumberland Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Cumberland Pharmaceuticals, Inc. - Dormant Projects
  • Cumberland Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Cumberland Pharmaceuticals, Inc., Key Information
  • Cumberland Pharmaceuticals, Inc., Key Facts
  • Cumberland Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Cumberland Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Cumberland Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Cumberland Pharmaceuticals, Inc. - Phase II, 2015
  • Cumberland Pharmaceuticals, Inc. - Preclinical, 2015
  • Cumberland Pharmaceuticals, Inc. - Discovery, 2015
  • Cumberland Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Cumberland Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Cumberland Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Cumberland Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Cumberland Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Cumberland Pharmaceuticals, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Cumberland Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Cumberland Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Cumberland Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Cumberland Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Cumberland Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Cumberland Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Cumberland Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top